arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

ImmunityBio, Inc.

IBRX
$7.63 ▲ +0.33 (+4.45%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
51 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
48
Health
Weak
Moderately Bearish
auto_awesome

Analytical Summary

ImmunityBio, Inc. faces fundamental challenges. Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $7.8B
Dividend Yield
Revenue Growth 167.6%
Op. Margin -157.9%
ROIC 8.0%
FCF / Share $-0.08
Trailing P/E
Price / Book
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

51-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$44.21M
↑ +167.6%
Net Income Profit after all expenses
$-632.78M
↓ -388.1%
Operating Margin Operating profit as % of sales
-157.9%
↑ +6.6% 0th
FCF / Share Free cash flow per share
$-0.08
↑ +26.4%
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
1
Returns
98
Financial Health
38
Cash Quality
59

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 14 years · 51 quarters